US FDA approves Hibsago for chronic hepatitis B

The US Food and Drug Administration has approved Hibsago, a GSK drug scientifically known as bepirovirsen, for treating chronic hepatitis B. The drug gives some adult patients the chance to stop long-term antiviral treatment.

AI-written summary of 3 sources; every verified point is backed by a verbatim quote. How Iyan works

• The approval allows some adults with chronic hepatitis B to stop antiviral treatment.

  «FDA-approved Hibsago could help some adults with chronic hepatitis B stop antiviral therapy.»

  Yahoo
• The drug is manufactured by GSK, and Reuters described it as offering patients the chance to end long-term treatment.

  «US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment»

  Reuters
• The drug's scientific name is bepirovirsen, and it has been approved for treating chronic hepatitis B, according to HCPLive.

  «FDA Approves Bepirovirsen for Chronic Hepatitis B»

  HCPLive
• A Yahoo report covers who qualifies for the drug, what the trials found, and the main risks.

  «Learn who qualifies, what trials found, and the key risks.»

  Yahoo

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms